Table 2.

Baseline characteristics and demographic data (ITT population)

CharacteristicC.E.R.A. (n = 162)Darbepoetin alfa (n = 162)
Male, n (%)70 (43)80 (49)
Mean (SD) age, yr63.9 (14.1)66.9 (12.8)
Mean (SD) weight, kg76.8 (16.2)80.5 (19.5)
Mean (SD) Hb, g/dl10.2 (0.6)10.2 (0.7)
Mean (SD) CrCl, ml/min27.7 (9.7)a27.0 (10.7)
Mean (SD) C-reactive protein, mg/L6.5 (11.1)b7.0 (14.2)
Mean (SD) albumin, g/L39.4 (5.2)c38.3 (5.3)d
Median (IQR) TSAT (%)23.7 (20.0–30.7)a23.7 (20.3–29.3)a
Median (IQR) ferritin, μg/L174.7 (107.7–271.3)185.8 (129.0–284.4)
Iron supplementation at baseline, %5554
Mean (SD) SBP, mmHg139 (18.9)a139 (20.9)a
Mean (SD) DBP, mmHg73 (10.5)a72 (10.7)a
Cause of renal failure %,
    diabetes4549
    hypertension/large vessel disease4044
    glomerulonephritis912
    interstitial nephritis/pyelonephritis66
    undefined cause73
    polycystic kidney disease46
    secondary glomerulonephritis/vasculitis12
    other hereditary/congenital diseases11
Previous and concomitant antihypertensive treatments, %
    angiotensin-converting enzyme inhibitors5148
    calcium channel blockers3940
    β adrenoceptor antagonists3940
    angiotensin II receptor blockers3735
Race, %
    white7081
    black2212
    Asian46
    other42
Ethnicity, %
    Hispanic1010
    non-Hispanic9090
Geographic region, %
    United States3536
    outside United States6564
  • IQR, interquartile range.

  • a n = 161 patients with evaluable measurements.

  • b n = 159 patients with evaluable measurements.

  • c n = 158 patients with evaluable measurements.

  • d n = 160 patients with evaluable measurements.